The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.

Inclusion criteria:

• Newly diagnosed patients (< 3years) with type 2 diabetes.
• Fasting plasma glucose (FPG) range of 126-240 mg/dL at Screening.
• No previous treatment with oral or parenteral glucose-lowering therapy.

Exclusion criteria:

• History of lactic acidosis.
• Anemia (<11g for males, <10 g for females).
• Unstable or severe NY Heart Association-class 3 or 4.
• Any NY Heart Association congestive heart failure.
• Patients with chronic diseases requiring periodic or intermittent treatment with oral or intravenous corticosteroids.

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.